Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mosunetuzumab by Genentech USA for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Mosunetuzumab is under clinical development by Genentech USA and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
Mosunetuzumab by Genentech USA for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Mosunetuzumab is under clinical development by Genentech USA and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
Mosunetuzumab by Genentech USA for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Mosunetuzumab is under clinical development by Genentech USA and currently in Phase III for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
Mosunetuzumab by Genentech USA for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Mosunetuzumab is under clinical development by Genentech USA and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...